Blog

Part 1 of 2 – Embracing a New Era of Dose Optimisation   For the last few years the FDA has been engaging with drug developers to reform how dose optimisation is approached for new cancer drugs. In August 2024 they finalised the eagerly-awaited guidance for industry “Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases” [1]. As part...

Leading mathematical modelling company, supporting oncology drug development.   A Transformative Year at Physiomics - Innovation, Collaboration and Success   As 2024 draws to a close, we’re taking a moment to look back on an incredible year at Physiomics plc. From strengthening collaborations with global leaders to expanding our capabilities and welcoming fantastic new talent to the team, it’s been a year of exciting progress, working alongside leaders in...

Leading mathematical modelling company, supporting oncology drug development.     From us to you - curated cutting-edge research and insights. Welcome to our newsletter, where we share the latest updates from Physiomics and offer insights on the pivotal news shaping the dynamic world of drug development.     Top news   Meet with the Physiomics team at BIO International!   Physiomics’ CEO, Peter Sargent, and Head of Business Development, Hayley Close will be joining >20,000...

Leading mathematical modelling company, supporting oncology drug development.     From us to you - curated cutting-edge research and insights. Welcome to our newsletter, where we share the latest updates from Physiomics and offer insights on the pivotal news shaping the dynamic world of drug development.     Top news   Exciting new project with existing large pharma client   Physiomics are pleased to share that we have been awarded a new PKPD modelling project...

Leading mathematical modelling company, supporting oncology drug development.     From us to you - curated cutting-edge research and insights. Welcome to our newsletter, where we share the latest updates from Physiomics and offer insights on the pivotal news shaping the dynamic world of drug development.     Top news     Welcoming Peter Sargent as newly appointed CEO   Peter, who joined Physiomics in September 2023 as Chief Operating Officer, has now been appointed to...

Leading mathematical modelling company, supporting oncology drug development. From us to you - our top moments of 2023! 2023 has been an eventful and exciting year for Physiomics, from welcoming new members to the team and moving to our new offices, to bringing new clients and collaborators onboard to work with us – it’s been a great year! Read on as we reflect on some of our...

Leading mathematical modelling company, supporting oncology drug development. From us to you - curated cutting-edge research and insights. Welcome to our newsletter, where we share the latest updates from Physiomics and offer insights on the pivotal news shaping the dynamic world of drug development.   Top news Meet us at AACR-NCI-EORTC! Physiomics is attending the AACR-NCI-EORTC International Conference on Molecular Targets And Cancer Therapeutics at the Hynes Convention Center, Boston on...

Pete joins us with experience working for a wide variety of life sciences businesses across R&D and commercial operations, read on to find out why he is excited to join Physiomics and where he sees the most potential!   Q: What attracted you to the role at Physiomics? A: “Having worked across the biopharma industry for many years, I’m acutely aware of the mounting pressures drug development companies...

Leading mathematical modelling company, supporting oncology drug development. From us to you - curated cutting-edge research and insights. Welcome to our newsletter, where we share the latest updates from Physiomics and offer insights on the pivotal news shaping the dynamic world of drug development.   Top news   Exciting new contract with Numab! We are pleased to announce that we have been awarded a further contract by existing client, Numab Therapeutics. The project...

Cancer therapies are often associated with a ‘Goldilocks Window’ of optimal dosing: striking a balance where efficacy is maximised and toxicity is minimised. While mathematical modelling offers a powerful tool to inform optimal treatment approaches in cancer drug development, determining the right level of mechanistic detail to include in a model also requires careful consideration – hitting the right balance is both art and science.   You...